Division of Radiation Oncology, European Institute of Oncology, Milan, Italy.
Radiother Oncol. 2013 Jan;106(1):21-7. doi: 10.1016/j.radonc.2012.10.018. Epub 2012 Dec 3.
To evaluate outcomes among early-stage breast cancer patients after conservative surgery and full-dose intraoperative radiotherapy electrons (ELIOT) by applying the Groupe Européen de Curiethérapie-European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) recommendations for partial breast irradiation (APBI).
One-thousand eight-hundred and twenty-two patients were stratified into the three GEC-ESTRO categories of "good candidates", "possible candidates" and "contraindication" in order to assess outcomes.
All the 1822 cases except 7 could be classified according to GEC-ESTRO groups: 573 patients met the criteria to be included in the "good candidates" group, 468 patients in the "possible candidates" group and 767 patients in the "contraindication" group. Median and mean follow-up length was 3.5 years (range 0-10.5 years) and 3.8 years (SD 2.2), respectively. The 5-year rate of in-breast tumor reappearances for "good candidates", "possible candidates" and "contraindication" groups were 1.9%, 7.4% and 7.7%, respectively (p 0.001). While the regional node relapse showed no difference, the rate of distant metastases was significantly different in the "contraindication" group compared to the other two categories, having a significant impact on survival.
Among the ELIOT population, the GEC-ESTRO recommendations enabled the selection of the good candidates with a low rate of local recurrence, but failed to differentiate the "possible candidates" and the "contraindication" groups.
通过应用欧洲放射肿瘤学会(ESTRO)和欧洲癌症研究与治疗组织(EORTC)局部乳腺照射(APBI)的部分乳房照射(PBI)建议,评估接受保乳手术和全剂量术中电子放疗(ELIOT)的早期乳腺癌患者的结果。
为了评估结果,将 1822 例患者分为 GEC-ESTRO 的三个类别:“合适的候选者”、“可能的候选者”和“禁忌证”。
除 7 例外,所有 1822 例患者均可根据 GEC-ESTRO 分组进行分类:573 例患者符合纳入“合适的候选者”组的标准,468 例患者符合纳入“可能的候选者”组的标准,767 例患者符合纳入“禁忌证”组的标准。中位和平均随访时间分别为 3.5 年(范围 0-10.5 年)和 3.8 年(SD 2.2)。“合适的候选者”、“可能的候选者”和“禁忌证”组的 5 年乳房内肿瘤复发率分别为 1.9%、7.4%和 7.7%(p<0.001)。虽然区域淋巴结复发无差异,但“禁忌证”组远处转移率明显高于其他两组,对生存有显著影响。
在 ELIOT 人群中,GEC-ESTRO 建议能够选择局部复发率低的合适的候选者,但未能区分“可能的候选者”和“禁忌证”组。